RecruitingPhase 1NCT06842589

Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cell Therapy in Patients With MDR-SRNS

Study of Therapeutic Efficacy of Anti-CD19 Chimeric Antigen Receptor T Lymphocytes (CAR-T) Cells in Patients With Multi-drug Resistant SRNS

Sponsor

The Children's Hospital of Zhejiang University School of Medicine

Enrollment

18 participants

Start Date

May 14, 2025

Study Type

INTERVENTIONAL

Conditions

CAR-T Cell Therapy Multi-Drug Resistant Nephrotic Syndrome

Summary

This is an investigator-initiated trial aimed at assessing the safety and efficacy of anti-CD19 CAR-T cells in the treatment of patients with Multi-drug resistant SRNS

Eligibility

Min Age: 2 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called anti-CD19 CAR-T cells for people with car-t cell therapy and multi-drug resistant nephrotic syndrome. The study is currently recruiting participants at 1 location. People eligible for this study include aged 2 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALanti-CD19 CAR-T cells

Three dose groups (0.3×105/kg, 1×105/kg, 3×105/kg) were set up, starting from the low dose group climbing to explore the safe and effective dose.

Locations(1)

Children's Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06842589

Related Trials

Exercise as an Immune Adjuvant for Allogeneic Cell Therapies

NCT066432211 location

Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients

NCT058586841 location